newsfilter
← Latest News
GlobeNewswire·

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further validates the